Hoe verhoudt SEQUENT's PS Ratio zich tot zijn concurrenten?

SEQUENT is een goede waarde op basis van zijn Price-To-Sales Ratio (3.4x) vergeleken met het gemiddelde van gelijken (5x).

Hoe verhoudt SEQUENT's PS Ratio zich tot andere bedrijven in de IN Pharmaceuticals industrie?

SEQUENT is duur op basis van de Price-To-Sales -ratio ( 3.4 x) vergeleken met het Indian Pharmaceuticals -industriegemiddelde ( 3.1 x).

Wat is SEQUENT's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Sales Fair Ratio van { SEQUENT te berekenen voor waarderinganalyse.

Wat is de reële prijs van SEQUENT als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van SEQUENT te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Sequent Scientific (NSEI:SEQUENT) - Aandelenkoers, Nieuws & Analyse

SEQUENT Overzicht aandelen

Sequent Scientific Limited is actief in de veterinaire gezondheidszorg in Europa, Azië en internationaal. Meer informatie

SEQUENT fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	3/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Dit jaar winstgevend geworden

Risicoanalyse

Rentebetalingen worden niet goed gedekt door de winsten

Volatiele aandelenkoers in de afgelopen 3 maanden

Sequent Scientific Limited Concurrenten

Jeena Sikho Lifecare

NSEI:JSLL

₹47.1b

Hikal

BSE:524735

₹47.6b

Aarti Pharmalabs

NSEI:AARTIPHARM

₹56.9b

Aarti Drugs

BSE:524348

₹42.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sequent Scientific
Historische aandelenkoersen
Huidige aandelenkoers	₹199.27
52 Week Hoogtepunt	₹240.70
52 Week Laag	₹92.05
Bèta	0.82
11 maand verandering	14.91%
3 maanden verandering	21.78%
1 Jaar Verandering	60.96%
33 jaar verandering	30.24%
5 jaar verandering	190.27%
Verandering sinds IPO	11.08%

Recent nieuws en updates

We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt

Sep 27

Recent updates

We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt

Sep 27

What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You

Sep 05

Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?

Jan 05

What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?

Dec 24

Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?

Dec 12

Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly

Nov 22

Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)

Nov 10

The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It

Oct 20

How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance?

Oct 05

Rendement voor aandeelhouders

	SEQUENT	IN Pharmaceuticals	IN Markt
7D	3.5%	0.8%	2.9%
1Y	61.0%	42.1%	28.9%

Rendement versus industrie: SEQUENT overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 42.1 % opleverde.

Rendement versus markt: SEQUENT overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 28.9 %.

Prijsvolatiliteit

Is SEQUENT's price volatile compared to industry and market?
SEQUENT volatility
SEQUENT Average Weekly Movement	8.3%
Pharmaceuticals Industry Average Movement	6.0%
Market Average Movement	6.1%
10% most volatile stocks in IN Market	9.0%
10% least volatile stocks in IN Market	4.0%

Stabiele aandelenkoers: De aandelenkoers van SEQUENT is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van SEQUENT is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Indian.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1985	1,195	Rajaram Narayanan	www.sequent.in

Sequent Scientific Limited is actief in de veterinaire gezondheidszorg in Europa, Azië en internationaal. Het bedrijf levert diergeneeskundige actieve farmaceutische ingrediënten (API's) op het gebied van anthelmintica, inclusief endo- en ectoparasiticiden; en antiprotozoa, nutraceutica, niet-steroïde ontstekingsremmers, anti-infectiva en dermatologie. Het biedt ook analytische oplossingen die API's, farmaceutische, persoonlijke verzorgings- en nutraceutische organisaties ondersteunen; en methodevalidatie, stabiliteit en microbiologie voor API's en eindproducten.

Sequent Scientific Limited Samenvatting

Hoe verhouden de winst en inkomsten van Sequent Scientific zich tot de beurswaarde?
SEQUENT fundamentele statistieken
Marktkapitalisatie	₹49.45b
Inkomsten(TTM)	₹164.81m
Inkomsten(TTM)	₹14.49b

300.0x

Koers/Winstverhouding

3.4x

P/S-verhouding

Is SEQUENT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SEQUENT resultatenrekening (TTM)
Inkomsten	₹14.49b
Kosten van inkomsten	₹8.10b
Brutowinst	₹6.39b
Overige uitgaven	₹6.23b
Inkomsten	₹164.81m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.66
Brutomarge	44.10%
Nettowinstmarge	1.14%
Schuld/Eigen Vermogen Verhouding	60.9%

Hoe presteerde SEQUENT op de lange termijn?

Bekijk historische prestaties en vergelijking

SEQUENT Overzicht aandelen

Beloningen

Risicoanalyse

Sequent Scientific Limited Concurrenten

NSEI:JSLL

₹47.1b

BSE:524735

₹47.6b

NSEI:AARTIPHARM

₹56.9b

BSE:524348

₹42.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024)

Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024

Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director

Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million

Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion.

We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt

Recent updates

Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024)

Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024

Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director

Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million

Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion.

We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt

What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You

Sequent Scientific Limited, Annual General Meeting, Sep 17, 2024

Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API

New minor risk - Share price stability

First quarter 2025 earnings released: EPS: ₹0.26 (vs ₹1.40 loss in 1Q 2024)

Sequent Scientific Limited to Report Q1, 2025 Results on Aug 14, 2024

Full year 2024 earnings released: ₹1.44 loss per share (vs ₹4.88 loss in FY 2023)

Sequent Scientific Limited to Report Q4, 2024 Results on May 15, 2024

Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)

Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024

Third quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.36 loss in 3Q 2023)

Sequent Scientific Limited Announces Executive Changes

Sequent Scientific Limited to Report Q3, 2024 Results on Feb 13, 2024

Sequent Scientific Limited Announces Resignation of Krunal Shah as Company Secretary & Compliance Officer, Effective on February 15, 2024

Sequent Scientific Limited to Report Q2, 2024 Results on Nov 06, 2023

Sequent Scientific Limited Announces Patri Venkat Raghavendra Rao as Chief Financial Officer

Sequent Scientific Limited, Annual General Meeting, Aug 30, 2023

Sequent Scientific Limited to Report Q1, 2024 Results on Aug 10, 2023

Sequent Scientific Limited Announces Discontinuation of Manufacturing Operations At Tarapur, Maharashtra

Full year 2023 earnings released: ₹4.88 loss per share (vs ₹1.67 profit in FY 2022)

Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet

Third quarter 2023 earnings released: ₹0.36 loss per share (vs ₹0.69 profit in 3Q 2022)

Sequent Scientific Limited Announces Resignation of Rahul Mukim as Director

Price target decreased to ₹149

High number of new and inexperienced directors

Second quarter 2023 earnings released: ₹0.15 loss per share (vs ₹0.58 profit in 2Q 2022)

Sequent Scientific Limited (BSE:512529) agreed to acquire Tineta Pharma Private Limited from group of shareholders for INR 2.18 billion.

Sequent Scientific Limited to Report Q2, 2023 Results on Nov 14, 2022

Sequent Scientific Limited, Annual General Meeting, Sep 20, 2022

First quarter 2023 earnings released: ₹0.57 loss per share (vs ₹0.04 profit in 1Q 2022)

Sequent Scientific Limited to Report Q1, 2023 Results on Aug 08, 2022

Investor sentiment improved over the past week

Sequent Scientific Limited Appoints P V Raghavendra Rao as the Chief Financial Officer

Investor sentiment deteriorated over the past week

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Sequent Scientific Limited to Report Q4, 2022 Results on May 25, 2022

Price target decreased to ₹170

High number of new and inexperienced directors

Sequent Scientific Limited Announces Resignation of Tushar Mistry Chief Financial Officer, Effective May 31, 2022

Sequent Scientific Limited Announces Resignation of Mr. Manish Gupta from the Position of CEO

Sequent Scientific Limited Announces Appointment of Rajaram Narayanan as Managing Director

CEO, MD & Executive Director recently sold ₹73m worth of stock

Investor sentiment improved over the past week

CEO, MD & Executive Director recently sold ₹84m worth of stock

CEO, MD & Executive Director recently sold ₹23m worth of stock

CEO, MD & Executive Director recently sold ₹27m worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to ₹197

Insider recently sold ₹5.7m worth of stock

Investor sentiment deteriorated over the past week

Insider recently bought ₹1.4m worth of stock

Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021)